Alzheimer’s Disease : Exceptional Level of First-in-Class Innovation and Diverse Range of Therapies in Development
Alzheimer’s Disease report provides Management and Treatment of Alzheimer’s Disease, Pipeline by Stage of Development and Molecule Type, First-in-Class Target Profiles and Strategic Consolidations
June 29, 2017 /MarketersMedia/ —
Alzheimer’s disease and Associated Indications, Exceptional Level of First-in-Class Innovation within Alzheimer’s disease, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression ocuses on Alzheimer’s disease alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden. Alzheimer’s disease pipeline is large, with 646 products in active development. In addition, the level of first-in-class innovation within the pipeline is exceptionally high – 65.3% of products with a disclosed molecular target have been identified as first-in-class. In comparison, the Pipeline for Alzheimer’s disease associated indications is smaller and less innovative. There are 272 products in development across the four associated indications, and only 27.7% of those with a disclosed molecular target are first in class. However, the diversity of first-in-class targets identified is greater than that of the Alzheimer’s disease pipeline.
Request Sample Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=1039051 .
The deals landscape for AD and AD-associated indications has been fairly active over the past decade. The aggregate deal value for licensing deals reached $13.0 billion, while the aggregate deal value for co-development deals totaled $10.7 billion. Small molecule products and those targeting GPCRs have dominated the landscape in terms of both deal frequency and aggregate value.
The prevalence of Alzheimer’s disease is escalating rapidly, largely as a result of aging populations. This will amplify the already substantial societal and economic costs of the disease over the coming decades. However, despite this large market opportunity, there are no disease-modifying therapies currently available that are capable of halting, reversing or effectively modifying the course of disease progression. Treatment options are extremely limited and can only temporarily slow the worsening of symptoms (Alzheimer’s Association, 2017 a; Yiannopoulou and Papageorgiou, 2013). Additionally, many aspects of the disease pathophysiology remain incompletely understood, and these knowledge gaps underlie the poor treatment options currently available to AD patients, and the failed attempts to improve on these therapies in clinical trials.
Get Discount on Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1039051 .
Moreover, this report allows you to:
• Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
• Identify leading products and key unmet needs within the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Direct Purchase This Report @ http://www.reportsnreports.com/purchase.aspx?name=1039051 .
Table of Contents:
• Executive Summary
• The Case for Innovation
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Signaling Network, Disease Causation and Innovation Alignment
• First-in-Class Target Profiles
• Strategic Consolidations
About Us:
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets.
Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsnreports.com
Organization: ReportsnReports
Address: Pune
Phone: +1-888-391-5441
For more information, please visit http://www.reportsnreports.com/reports/1039051-frontier-pharma-alzheimers-disease-and-associated-indications-exceptional-level-of-first-in-class-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression.html
Source: MarketersMedia
Release ID: 212163
Copyright © 1999-2013 SproutNews.com
